Patents Assigned to Fluent Biosciences Inc.
-
Patent number: 11976325Abstract: The invention provides systems and methods for making sequencing libraries that are useful for quantitatively analyzing nucleic acids in a sample. Sample nucleic acids are randomly cleaved at, and PCR handled are attached to, a random cut site. The nucleic acid is amplified into a sequencing library in which a sequencing primer generates a sequence read from adjacent the random cut site. The sequence reads can be mapped to a reference, but they will also include a unique identifier sequence that comes from within the nucleic acid molecule being analyzed, i.e., an intrinsic molecular identifier (IMI). The IMI is unique for each molecule and can thus be used to deduplicate sequence reads originating from the same molecule.Type: GrantFiled: April 6, 2023Date of Patent: May 7, 2024Assignee: FLUENT BIOSCIENCES INC.Inventor: Robert Meltzer
-
Publication number: 20240117423Abstract: The invention provides systems and methods for making sequencing libraries that are useful for quantitatively analyzing nucleic acids in a sample. Sample nucleic acids are randomly cleaved at, and PCR handled are attached to, a random cut site. The nucleic acid is amplified into a sequencing library in which a sequencing primer generates a sequence read from adjacent the random cut site. The sequence reads can be mapped to a reference, but they will also include a unique identifier sequence that comes from within the nucleic acid molecule being analyzed, i.e., an intrinsic molecular identifier (IMI). The IMI is unique for each molecule and can thus be used to deduplicate sequence reads originating from the same molecule.Type: ApplicationFiled: April 6, 2023Publication date: April 11, 2024Applicant: FLUENT BIOSCIENCES INC.Inventor: Robert Meltzer
-
Patent number: 11866782Abstract: This disclosure provides methods and systems for single-cell, multi-omic analysis of target cells without microfluidic devices. The disclosed methods involve the use of template particles to template the formation of monodisperse droplets to generally capture a single target cell from a population of cells in an encapsulation, derive a plurality of distinct mRNA molecules from the single target cell, and quantify the distinct mRNA molecules to generate an expression profile. Nucleic-acid-tagged antibody conjugates are used for simultaneous proteomic analysis along with the gene expression profiling.Type: GrantFiled: March 16, 2021Date of Patent: January 9, 2024Assignee: Fluent Biosciences Inc.Inventor: Sepehr Kiani
-
Patent number: 11827936Abstract: This disclosure provides methods and systems for single-cell analysis, including single-cell transcriptome analysis, of target cells without microfluidic devices. The disclosed methods involve the use of template particles to template the formation of monodisperse droplets to generally capture a single target cell from a population of cells in an encapsulation, derive a plurality of distinct mRNA molecules from the single target cell, and quantify the distinct mRNA molecules to generate an expression profile.Type: GrantFiled: January 12, 2021Date of Patent: November 28, 2023Assignee: Fluent Biosciences Inc.Inventors: Kristina Fontanez, Robert Meltzer, Yi Xue, Christopher D'amato, Sepehr Kiani
-
Patent number: 11773452Abstract: The disclosure provides methods and systems of analyzing single cells by simultaneously separating cells into monodisperse droplets and tagging each nucleic acid molecule from the cells with barcodes unique to each droplet. The methods and systems combine template particles with a plurality of single cells in a tube, generate in the tube monodispersed droplets encapsulating a single one of the template particles and a single one of the single cells, release nucleic acid molecules from the single cells and provide each nucleic acid molecule with a barcode unique to the respective droplet. The nucleic acid molecules can then be analyzed by any known method, for example by sequencing the nucleic acid molecules.Type: GrantFiled: August 20, 2021Date of Patent: October 3, 2023Assignee: Fluent Biosciences Inc.Inventors: Kristina Fontanez, Robert Meltzer, Yi Xue, Sepehr Kiani
-
Patent number: 11512337Abstract: The invention provides methods and systems for drug screening by segregating single cells into droplets simultaneously and providing candidate compound to the single cells to measure cellular response. Methods of the present invention combine template particles with a plurality of single cells in a tube, generate in the tube monodispersed droplets simultaneously that encapsulate a single one of the template particles and single one of the single cells, provide to the single cells one or more candidate compounds, and measure a cellular response to the one or more candidate compounds.Type: GrantFiled: January 12, 2021Date of Patent: November 29, 2022Assignee: FLUENT BIOSCIENCES INC.Inventors: Kristina Fontanez, Robert Meltzer, Yi Xue, Sepehr Kiani
-
Publication number: 20220372561Abstract: This invention releases to systems and methods for detecting the presence and quantity of a target nucleic acid in a sample using dPCR and PIP encapsulated monodisperse droplets.Type: ApplicationFiled: May 18, 2022Publication date: November 24, 2022Applicant: Fluent Biosciences Inc.Inventors: Sepehr Kiani, Aaron Weber, Robert Meltzer
-
Patent number: 11104961Abstract: The disclosure provides methods and systems of analyzing single cells by simultaneously separating cells into monodisperse droplets and tagging each nucleic acid molecule from the cells with barcodes unique to each droplet. The methods and systems combine template particles with a plurality of single cells in a tube, generate in the tube monodispersed droplets encapsulating a single one of the template particles and a single one of the single cells, release nucleic acid molecules from the single cells and provide each nucleic acid molecule with a barcode unique to the respective droplet. The nucleic acid molecules can then be analyzed by any known method, for example by sequencing the nucleic acid molecules.Type: GrantFiled: January 12, 2021Date of Patent: August 31, 2021Assignee: Fluent Biosciences Inc.Inventors: Kristina Fontanez, Robert Meltzer, Yi Xue, Sepehr Kiani